1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-1H-pyrazole-4-carboxylic acid

Catalog No. :
ACESVF143
CAS No. :
1034976-50-5
Molecular Formula :
C14H21N3O4
Molecular Weight :
295.34

IUPAC Name:1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazole-4-carboxylic acid

1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-1H-pyrazole-4-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$389.00Login to see priceInquiryInquiry
100mg95%$578.00Login to see priceInquiryInquiry
250mg95%$820.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-1H-pyrazole-4-carboxylic acid
IUPAC Name1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazole-4-carboxylic acid
MDL No.MFCD14585369
Molecular FormulaC14H21N3O4
Molecular Weight295.34
SMILESO=C(C1=CN(C2CCN(C(OC(C)(C)C)=O)CC2)N=C1)O
InChI KeyXUZBQTPCOHAVQD-UHFFFAOYSA-N
Synonym4-(4-Carboxy-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester;1-Piperidinecarboxylic acid, 4-(4-carboxy-1H-pyrazol-1-yl)-, 1-(1,1-dimethylethyl) ester
CAS No.1034976-50-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACESVF143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACESVF143 route product structure diagram
    ACESVF1431034976-50-5
Inquiry

2. ACESVF143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACUIWR580 route compound structure diagram
    ACUIWR58037622-90-5 In Stock
  4. Then
  5. ACESVF143 route product structure diagram
    ACESVF1431034976-50-5
Inquiry

Comments (0)